African Journal of
Biochemistry and Molecular Biology Research

ISSN : 3434-6120

Index: Harvard, Boston, Sydney University, Dimensions, Lens, ResearchGet Scilit, Semantic, Google Scholar, Base etc

https://doi.org/10.58578/AJBMBR.v2i2.5326

The Future of Gene Therapy: Revolutionizing Modern Medicine

Muhammad Akram[1], Alam Afroz Urooj Khan[2], Isaac John Umaru[3]
[1,2]Government College University Faisalabad, Pakistan
[3]Federal University Wukari, Taraba State, Nigeria
makram_0451@yahoo.com

Article Info:

Submitted:	Revised:	Accepted:	Published:
Mar 3, 2025	Mar 18, 2025	Mar 30, 2025	Apr 5, 2025

Abstract

The use of gene therapy paired with advanced technology may one day enable chronic illnesses, cancerous diseases, and even genetic defects to be treated via DNA alterations. With developments and promising results in gene CRISPR-Cas9 editing technology, improved treatments and promising results from clinical trials have made gene therapy a possibility. It is also predicted that gene therapy will be used in the future to combat heart issues, cancer, neurological diseases, and other hereditary attributes. Nonetheless, metastatic issues pertaining to ethics, engagement, spending, and the probability of negative consequences over time still remain. In the case of augmented medicine, incorporating stem cells with new artificial intelligence technology will ensure better and more accurate treatment along with greater personalization of gene therapies. This is expected to lead to a whole new realm of precision medicine.

Keywords: Gene therapy, Genetic ailments, CRISPR-Cas9, Gene splicing, Somatic genetic therapy, Germline genetic therapy, Viral delivery systems, Non-viral delivery systems

AJBMBR Journal is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License

Introduction

Noteworthy fields in the modern medicine stratum, therapy of genes stands out. It has the expected capability to resolve obstinate medical conditions, several types of cancer, and other hereditary issues. If Researchers concentrate on the existing genetic deviations, they could craft medicines that work and even have a shelf-life of a lifetime (Mehta et al 2017). With the integration of powerful editing tools, delivery systems, and clinical applications in recent years, treatment of genes is efficiently progressing towards being an automated procedure. In this section, we explore the most recent advancements, uses, problems, and opportunities in gene therapy.

Understanding Gene Therapy

With gene therapy, one seeks to modify or replace defective genes in a person's cells in an attempt to cure or prevent a disease diagnosis. There are two main types, somatic and germline gene therapy. While somatic gene therapy is considered non-reproductive and applies to non-division cells, thus it is modern and clinically used to fix several genetic defects, for example, Deletion mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, anomalies in the SLC26A4 or PAX8 or Hearing Loss (Zhu et al 2023). In contrast, germline gene therapy is the technique responsible for passing down genetically altered sperm and egg cells to descendants, and because of some ethical issues regarding his unknown troubles, remains limited in its therapeutic uses. These two methods can be administered by ex vivo where cells are altered and reintroduced or in vivo genetic material is inserted directly into the body. And because of progressive advancements in medicine, these two strategies have become more effective and safer, thus more promising for treatment of genetic disorders.

Recent Advancements in Gene Therapy

1. CRISPR-Cas9 and Other Gene-Editing Technologies

The technology that enables efficient DNA alteration, like CRISPR (short for Clustered Regularly Interspaced Short Palindromic Repeats), has made gene editing processes simpler and cheaper. Diseases such as sickle cell anemia, cystic fibrosis, and specific types of cancer can now be treated using CRISPR-Cas9, base editing, and prime editing techniques (Ferrie

et al 2024). These days scientists are working on advancing the accuracy of CRISPR while minimizing unintended consequences.

2. Viral and Non-Viral Vectors for Gene Delivery

The achievement of a gene therapy procedure is highly reliant on the method of and the means by which the therapy is delivered. Several gene therapy vectors have been designed to insert therapeutic genes into cells:

- Viral Vectors: The use of lentiviruses, retroviruses and adeno associated viruses (AAVs) is common practice as they are able to insert genetic material into the cells. AAV gene therapies have been approved for spinal muscular atrophy and retinal dystrophy.

- Non-Viral Vectors: More safe methods of gene transfer such as lipid nanoparticles and electroporation are also used, which have less chances of provoking an immune response (Lambricht et al 2016). These methods are being studied as well for mRNA based gene therapies.

3. Gene Therapy for Inherited Disorders

Recent clinical trials for Spinal Muscular Atrophy (SMA), Hemophilia, and Duchenne Muscular Dystrophy have successfully utilized gene therapy, outperforming expectations regarding patient improvement as well as their long-term outcomes, suggesting that other genetic conditions could now benefit from these therapies (Jensen et al 2021).

Applications of Gene Therapy

Gene therapy is being researched for a variety of health issues. The most relevant is in:

1. Oncology: The treatment of cancer using immune cells is considered the most advanced area of gene therapy. CAR-T therapy is the immunoediting approach which enhances the T-cells ability to recognize and destroy cancer cells. It has been very effective in treating haematologic cancers such as leukaemia and lymphoma.

2. Genetics of Behavior: Gene therapy is referred to for neurodegenerative conditions. Research is being focus on Parkinson's, Alzheimer's and Huntington's disease (Pantiya et al 2020). Scientists are trying to decrease protective factors further of disease progression by delivering correcting genes or stopping the protective factors.

3. Cardiac: Various makes an attempt are being done to develop genetic therapies for treatment of heart failures by regenerating the damaged heart muscles or blood vessels of a person, and eliminating the genetic predisposition of a person to suffer from heart diseases.

4. Pediatrics: There are attempts to apply the gene therapy principles for the abovementioned disorders in children in order to boost teh immune linked reactions against teh hepatitis virus, HIV, and potentially dangerous novel viruses like Covid 19. Modified immune cells represent one method to abolish the infection by viruses.

5. Eye: FDA approved therapies for genetic disorders that causes retinal degeneration and blindness includes Luxturna and a few others (Gordon et al 2019). These therapies are capable of achieving vision restoration in patients with genetic defects of the retina.

Challenges in Gene Therapy

Although there has been advancement in therapies aimed at modifying genetic defects, issues still remain which would have to be solved in order for these therapies to be adopted broadly.

1. Ethical and regulatory: The difficulties associated with ethical principles are especially poignant when it comes to human genetic modifications, such as germline editing (Lappé et al 1991). There is the worry of designer babies, unintended consequences, and negative impacts that may be suffered by future generations.

2. Mechanisms of delivery: The safe and effective delivery of genetic material to particular target cells lacks methodical mechanisms. Even if viral vectors are effective, they can activate undesirable immunological reactions, and non-viral ones are constantly being developed to make them effective.

3. Affordability: Gene therapy is financially out of reach for the most susceptible individuals (Wong et al 2021). As an example, Zolgensma, a treatment for SMA, has a price tag of more than $2 million for each patient.

Future Prospects of Gene Therapy

It's anticipated that gene therapy would advance in accuracy, cost, and accessibility with ongoing research and technical advancements. Some of the most exciting prospects include:

Personalized Medicine: As genomic sequencing becomes more accessible, gene therapy treatments can be tailored to a patient's genetic profile, improving efficacy and lowering hazards (Salzman et al 2018).

AI and Machine Learning in Gene Therapy: Computational methods are being developed to anticipate gene editing results, boost target specificity, and optimise delivery routes in order to maximise the effectiveness of gene therapy.

Advancements in Stem Cell-Based Gene Therapy: Combining gene therapy with stem cell research holds significant promise for treating complicated diseases like diabetes, neurological problems, and organ regeneration (Hussen et al 2024).

Gene Therapy for Aging and Longevity: In an effort to extend life expectancy and enhance general health in later years, researchers are investigating gene treatments that target genes associated with ageing.

Conclusion

Despite its promise, gene therapy presents a new frontier in medicine that is challenging for treating previously incurable diseases. Regardless of the problems, most still believe that further research and development will advance the seemingly unreachable limits of the search for healthier living. It is necessary to set legal regulations and ethical who can justifiably enforce such powerful devices within scientific developments to ensure total control. There is a tendency in foreseeing favorable outcomes with these adjustments, especially with the shift towards aiding genetic malfunctions similarly to the way precision medicine does.

Reference

Ferrie, J. (2024). The advantages of base and prime editing over traditional CRISPR in the treatment of monogenic diseases. International Journal of High School Research, 6, 45-51.

Gordon, K., Del Medico, A., Sander, I., Kumar, A., & Hamad, B. (2019). Gene therapies in ophthalmic diseases. Nature Reviews Drug Discovery, 18, 415-416.

Hussen, B. M., Taheri, M., Yashooa, R. K., Abdullah, G. H., Abdullah, S. R., Kheder, R. K., & Mustafa, S. A. (2024). Revolutionizing medicine: Recent developments and future prospects in stem-cell therapy. International Journal of Surgery, 110(12), 8002-8024

Jensen, T. L., Gøtzsche, C. R., & Woldbye, D. P. (2021). Current and future prospects for gene therapy for rare genetic diseases affecting the brain and spinal cord. Frontiers in Molecular Neuroscience, 14, 695937.

Lambricht, L., Lopes, A., Kos, S., Sersa, G., Préat, V., & Vandermeulen, G. (2016). Clinical potential of electroporation for gene therapy and DNA vaccine delivery. Expert Opinion on Drug Delivery, 13(2), 295-310.

Lappé, M. (1991). Ethical issues in manipulating the human germ line. The Journal of Medicine and Philosophy, 16(6), 621-639

Mehta, P., & Bhayani, D. (2017). Impact of space environment on stability of medicines: Challenges and prospects. Journal of Pharmaceutical and Biomedical Analysis, 136, 111-119.

Pantiya, P., Thonusin, C., Chattipakorn, N., & Chattipakorn, S. C. (2020). Mitochondrial abnormalities in neurodegenerative models and possible interventions: Focus on Alzheimer's disease, Parkinson's disease, Huntington's disease. Mitochondrion, 55, 14-47.

Salzman, R., Cook, F., Hunt, T., Malech, H. L., Reilly, P., Foss-Campbell, B., & Barrett, D. (2018). Addressing the value of gene therapy and enhancing patient access to transformative treatments. Molecular Therapy, 26(12), 2717-2726.

Zhu, K., & Jin, Y. (2023). Case report: A case of SLC26A4 mutations causing Pendred syndrome and non-cystic fibrosis bronchiectasis. Frontiers in Pediatrics, 10, 1077878.

Wong, C. H., Li, D., Wang, N., Gruber, J., Conti, R. M., & Lo, A. W. (2021). Estimating the financial impact of gene therapy in the US (Working Paper No. 28744). National Bureau of Economic